ClinicalTrials.gg
RecruitingNCT04899466Updated Nov 15, 2024

Efficacy Evaluation of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence

An interventional study of ActiGraft in Dehiscence Wound, sponsored by RedDress Ltd.. Recruiting at 1 site in Israel. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by RedDress Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This is a prospective, single arm study, consisting of 20 women with abdominal surgical wound dehiscence that requires secondary closure. The participants will receive a weekly application of ActiGraft for 4 weeks, or until complete healing of the wound (the earlier of the two).

An historic matched-control group of 20 patients will be compared retrospectively

02

Conditions studied

  • Dehiscence Wound
03

In context

Lead sponsor

RedDress Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Women that had a laparotomy no more than 3 weeks before accrual.
  • Surgical wound dehiscence that requires a secondary closure.
  • Time from wound dehiscence >24 hours and \<6 days.
  • The open wound includes epidermis, dermis and sub cutaneous fat.
  • The patient can sign an form.

Exclusion criteria

Exclusion Criteria:

  • Patients with necrotizing fasciitis
  • Patients with fascial dehiscence
  • Cannot withdraw blood in the required amount (up to 18 mL per week).
  • Known coagulation problems, abnormal level or if heparin is given intravenously. Subjects who are taking oral anti-coagulants or anti-agreganrts will not be excluded.
  • Pregnancy
  • Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive systemic (Prednisone- more than 10mg/d or equivalent).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    ActiGraft

    Whole blood clot (WBC) gel

    Device: ActiGraft

Interventions

  • DeviceActiGraft

    Whole blood clot (WBC) gel

06

What researchers measure

Primary outcomes

  1. Incidence of complete wound closure

    Skin re-epithelialization without drainage or dressing requirements

    Time frame: 4 weeks

Secondary outcomes

  1. Wound Percent Area Reduction (PAR)

    The change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage.

    Time frame: 2, 4 and 6 weeks

  2. Mean time of complete wound closure

    Skin re-epithelialization without drainage or dressing requirements

    Time frame: 4 weeks

  3. Durability of wound closure 2 weeks after complete healing

    No wound dehiscence

    Time frame: Up to 6 weeks

  4. Comparison of time to complete closure between study cases and historic control

    Skin re-epithelialization without drainage or dressing requirements

    Time frame: 4 weeks

Other outcomes

  1. Change in pain level

    Measured by Numeric Rating Scale (0 - no pain at all to 10 - worst pain) weekly for 4 weeks post ActiGraft application

    Time frame: 1, 2, 3 and 4 weeks

  2. Patient satisfaction

    Will be assessed by subject satisfaction survey using a 5-point Likert Scale (the higher score means a better outcome).

    Time frame: 1, 2, 3, 4, 6 weeks and 42 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The results will be part of several scientific publications

Supporting information: Study protocol

Time frame: Upon publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Aug 2026, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2021
First posted
May 24, 2021
StartActual
Aug 1, 2021
Primary completionEst.
Aug 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04899466
Lead sponsor
RedDress Ltd.
Responsible party
Sponsor
First posted
May 24, 2021
Start date
Aug 1, 2021
Primary completion
Aug 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Nov 15, 2024

Study contacts

Sharon Sirota
Contact
sharon@reddress.co.il
+972545800765
Sharon Sirota
study director · RedDress Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion